PL336464A1 - Method of and compositions for modulating reactivity in respect to corticosteroids i - Google Patents
Method of and compositions for modulating reactivity in respect to corticosteroids iInfo
- Publication number
- PL336464A1 PL336464A1 PL98336464A PL33646498A PL336464A1 PL 336464 A1 PL336464 A1 PL 336464A1 PL 98336464 A PL98336464 A PL 98336464A PL 33646498 A PL33646498 A PL 33646498A PL 336464 A1 PL336464 A1 PL 336464A1
- Authority
- PL
- Poland
- Prior art keywords
- corticosteroids
- compositions
- respect
- reactivity
- modulating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Heart & Thoracic Surgery (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Cell Biology (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Transplantation (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/820,692 US6054487A (en) | 1997-03-18 | 1997-03-18 | Methods and compositions for modulating responsiveness to corticosteroids |
US1634698A | 1998-01-30 | 1998-01-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
PL336464A1 true PL336464A1 (en) | 2000-06-19 |
Family
ID=26688484
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL98336464A PL336464A1 (en) | 1997-03-18 | 1998-03-12 | Method of and compositions for modulating reactivity in respect to corticosteroids i |
Country Status (20)
Country | Link |
---|---|
EP (1) | EP0998300A1 (de) |
JP (1) | JP2002504091A (de) |
KR (1) | KR20000076420A (de) |
CN (1) | CN1269722A (de) |
AU (1) | AU734756B2 (de) |
BG (1) | BG103808A (de) |
BR (1) | BR9810409A (de) |
CA (1) | CA2282845A1 (de) |
DE (1) | DE998300T1 (de) |
ES (1) | ES2146192T1 (de) |
HU (1) | HUP0104439A3 (de) |
ID (1) | ID22975A (de) |
IL (1) | IL131815A0 (de) |
NO (1) | NO994506L (de) |
NZ (1) | NZ337769A (de) |
PL (1) | PL336464A1 (de) |
SI (1) | SI20110A (de) |
SK (1) | SK122199A3 (de) |
TR (1) | TR199902615T2 (de) |
WO (1) | WO1998041232A2 (de) |
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US6706264B1 (en) | 1994-03-14 | 2004-03-16 | Genetics Institute, Llc | Use of IL-12 antagonists in the treatment of conditions promoted by an increase in levels of IFN-y |
ZA95960B (en) * | 1994-03-14 | 1995-10-10 | Genetics Inst | Use of interleukin-12 antagonists in the treatment of autoimmune diseases |
IL121860A0 (en) | 1997-08-14 | 1998-02-22 | Yeda Res & Dev | Interleukin-18 binding proteins their preparation and use |
US7704944B2 (en) | 1997-08-14 | 2010-04-27 | Yeda Research And Development Company Ltd. | Interleukin-18 binding proteins, their preparation and use for the treatment of sepsis |
US7220717B2 (en) | 1997-08-14 | 2007-05-22 | Yeda Research And Development Company Ltd. | Interleukin-18 binding proteins, their preparation and use |
US6184210B1 (en) | 1997-10-10 | 2001-02-06 | Cytovia, Inc. | Dipeptide apoptosis inhibitors and the use thereof |
AR015966A1 (es) * | 1997-10-17 | 2001-05-30 | Smithkline Beecham Corp | Uso de un compuesto inhibidor de pde4 para la preparacion de un medicamento util para el tratamiento de prurito |
AU744302B2 (en) * | 1997-10-31 | 2002-02-21 | Beth Israel Deaconess Medical Center | Use of anti-IL-12 antibodies in transplantation rejection |
EP1516630A3 (de) * | 1997-10-31 | 2006-05-03 | Wyeth | Verwendung von anti-il-12 Antikörpern bei Transplantationsabstossungen |
WO1999025737A1 (en) * | 1997-11-19 | 1999-05-27 | Tanox Pharma B.V. | Compositions and methods for treatment of autoimmune diseases, using a monoclonal antibody to the interleukin-12 beta2-chain |
CA2323439A1 (en) * | 1998-03-16 | 1999-09-23 | Cytovia, Inc. | Dipeptide caspase inhibitors and the use thereof |
WO2001045747A1 (en) * | 1998-11-27 | 2001-06-28 | Technion Research & Development Foundation Ltd. | Interferon gamma inducing factor based vaccine and use of same for protective immunity against multiple sclerosis |
AU1843200A (en) * | 1998-12-09 | 2000-06-26 | Protein Design Labs, Inc. | Animal model for psoriasis for the prevention and treatment of psoriasis in humans |
ATE336480T1 (de) | 1999-03-16 | 2006-09-15 | Cytovia Inc | Substituierte 2-aminobenzamin caspase inhibitoren und ihre verwendung |
US7883704B2 (en) | 1999-03-25 | 2011-02-08 | Abbott Gmbh & Co. Kg | Methods for inhibiting the activity of the P40 subunit of human IL-12 |
US6914128B1 (en) | 1999-03-25 | 2005-07-05 | Abbott Gmbh & Co. Kg | Human antibodies that bind human IL-12 and methods for producing |
DE19915465A1 (de) * | 1999-04-06 | 2000-10-19 | Apotech Res & Dev Ltd | Verwendung eines Caspase-Inhibitors zur Proliferationshemmung von Zellen und Verwendung eines oder mehrerer Caspase-Inhibitors/en zur Behandlung von Erkrankungen beruhend auf Lymphozyten-Hyperproliferation oder zur Suppression einer Immunantwort durch Lymphozyten |
WO2000061542A1 (en) | 1999-04-09 | 2000-10-19 | Cytovia, Inc. | Caspase inhibitors and the use thereof |
IL131047A0 (en) | 1999-07-22 | 2001-01-28 | Yeda Res & Dev | Use of il-18 inhibitors |
WO2001016093A1 (en) | 1999-08-27 | 2001-03-08 | Cytovia, Inc. | SUBSTITUTED α-HYDROXY ACID CASPASE INHIBITORS AND THE USE THEREOF |
AU7127600A (en) * | 1999-09-17 | 2001-04-17 | Basf Aktiengesellschaft | Methods and compositions for modulating responsiveness to corticosteroids |
US6566338B1 (en) | 1999-10-12 | 2003-05-20 | Cytovia, Inc. | Caspase inhibitors for the treatment and prevention of chemotherapy and radiation therapy induced cell death |
TWI335336B (de) | 2000-02-10 | 2011-01-01 | Abbott Gmbh & Co Kg | |
WO2001093909A2 (en) * | 2000-06-06 | 2001-12-13 | Glaxo Group Limited | Cancer treatment composition containing an anti-neoplastic agent and a pde4 inhibitor |
AU7250301A (en) * | 2000-06-22 | 2002-01-02 | Willy Ben Moussa Ben Mohammed | Use of glucocorticosteroids for producing a medicament to treat oligotrichia |
US20020025317A1 (en) * | 2000-07-20 | 2002-02-28 | Schering Ag | Bispecific monoclonal antibodies to IL-12 and IL-18 |
WO2002022127A1 (en) * | 2000-09-13 | 2002-03-21 | Isis Innovation Limited | Use of phosphodiesterase inhibitors for the treatment of anorectal disorders |
EP1188438A1 (de) * | 2000-09-15 | 2002-03-20 | Warner-Lambert Company | Pharmazeutische Zusammensetzungen zur Vorbeugung oder Behandlung von mit IL-12 Überproduktion assozierten Erkrankungen |
EP1199074A1 (de) * | 2000-09-15 | 2002-04-24 | Warner-Lambert Company | Pharmazeutische Zusammensetzungen zur Vorbeugung oder Behandlung von mit IL-12 Überproduktion assozierten Erkrankungen |
EP1355668B1 (de) * | 2001-01-29 | 2007-12-12 | Laboratoires Serono SA | Verwendung von il-18 hemmern zur behandlung und/oder prävention von herzkrankheiten |
IL158866A0 (en) * | 2001-05-16 | 2004-05-12 | Yeda Res & Dev | Use of il-18 inhibitors for the treatment or prevention of sepsis |
DE60235989D1 (de) | 2001-06-26 | 2010-05-27 | Amgen Fremont Inc | Antikörper gegen opgl |
EP1448205B1 (de) * | 2001-10-05 | 2011-03-23 | Zalicus Inc. | Kombinationen für die behandlung von immun-entzündlichen erkrankungen |
JP2003342196A (ja) * | 2002-05-31 | 2003-12-03 | Mukku:Kk | 静脈注射用組成物、その製造法およびその製剤 |
EP1553955A4 (de) * | 2002-09-24 | 2008-11-05 | Combinatorx Inc | Verfahren und reagenzien zur behandlung von erkrankungen und störungen im zusammenhang mit erhöhten spiegeln von entzündungsfördernden zytokinen |
WO2004028545A1 (en) * | 2002-09-25 | 2004-04-08 | Astrazeneca Ab | A COMBINATION OF A LONG-ACTING β2-AGONIST AND A GLUCOCORTICOSTEROID IN THE TREATMENT OF FIBROTIC DISEASES |
US20060083714A1 (en) * | 2003-01-27 | 2006-04-20 | Warner James M | Combination of a pde iv inhibitor and a tnf-alpha antagonist |
US20050100965A1 (en) | 2003-11-12 | 2005-05-12 | Tariq Ghayur | IL-18 binding proteins |
CA2566877A1 (en) * | 2004-05-17 | 2005-11-24 | Keio University | Medicinal composition and therapeutic method |
GB0411056D0 (en) | 2004-05-18 | 2004-06-23 | Novartis Ag | Organic compounds |
DK1808446T3 (da) | 2004-07-16 | 2012-05-14 | Atsuo Sekiyama | IL-18-receptor-antagonist og farmaceutisk sammensætning indeholdende antagonisten |
JPWO2006041121A1 (ja) * | 2004-10-13 | 2008-05-15 | 協和醗酵工業株式会社 | 慢性皮膚疾患の治療および/または予防剤 |
AU2006270165B2 (en) | 2005-07-14 | 2010-03-11 | Neothetics, Inc. | Sustained release enhanced lipolytic formulation for regional adipose tissue treatment |
PL2077830T3 (pl) * | 2006-10-17 | 2013-04-30 | Lithera Inc | Sposoby, kompozycje i formulacje do leczenia orbitopatii tarczycowej |
RU2475265C2 (ru) | 2007-01-16 | 2013-02-20 | Эбботт Лэборетриз | Способы лечения псориаза |
AU2008233173B2 (en) | 2007-03-29 | 2013-09-19 | Abbvie Inc. | Crystalline anti-human IL-12 antibodies |
TWI461210B (zh) | 2008-03-18 | 2014-11-21 | Abbvie Inc | 治療牛皮癬的方法 |
US9132084B2 (en) | 2009-05-27 | 2015-09-15 | Neothetics, Inc. | Methods for administration and formulations for the treatment of regional adipose tissue |
GEP201606551B (en) | 2010-11-24 | 2016-10-10 | Novamedica Llc | Selective, lipophilic, and long-acting beta agonists monotherapeutic formulations tions and methods for cosmetic treatment of adiposity and contour bulging |
WO2015063669A1 (en) | 2013-10-30 | 2015-05-07 | Wockhardt Limited | Pharmaceutical compositions comprising combination of roflumilast and acebrophylline or pharmaceutically acceptable salts thereof |
CA3231766A1 (en) * | 2021-09-22 | 2023-03-30 | Elizabeth W. JEFFORDS | Methods of treating ocular inflammatory diseases |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3320125A (en) * | 1964-04-28 | 1967-05-16 | Merck & Co Inc | Inhalation aerosol composition |
CA2024872C (en) * | 1989-09-08 | 2002-07-09 | James Barry Douglas Palmer | Medicaments |
IL104068A (en) * | 1991-12-12 | 1998-10-30 | Glaxo Group Ltd | Pharmaceutical preparations in a spray without surfactant containing 1, 1, 1, 2 tetrafluoroethane or 1,1,2,3,3 petafluor N propane as propellant |
GB9202519D0 (en) * | 1992-02-06 | 1992-03-25 | Glaxo Group Ltd | Medicaments |
MX9304585A (es) * | 1992-07-31 | 1994-03-31 | Glaxo Group Ltd | Formulacion farmaceutica en aerosol, lata adecuada para liberar la formulacion e inhalador de dosis dosificada que comprende la lata. |
GB9426252D0 (en) * | 1994-12-24 | 1995-02-22 | Glaxo Group Ltd | Pharmaceutical composition |
AP835A (en) * | 1995-04-14 | 2000-05-12 | Glaxo Wellcome Inc | Metered dose inhaler for beclomethasone dipropionate. |
-
1998
- 1998-03-12 DE DE0998300T patent/DE998300T1/de active Pending
- 1998-03-12 HU HU0104439A patent/HUP0104439A3/hu unknown
- 1998-03-12 AU AU67604/98A patent/AU734756B2/en not_active Ceased
- 1998-03-12 EP EP98912929A patent/EP0998300A1/de not_active Withdrawn
- 1998-03-12 ID IDW991185A patent/ID22975A/id unknown
- 1998-03-12 CA CA002282845A patent/CA2282845A1/en not_active Abandoned
- 1998-03-12 IL IL13181598A patent/IL131815A0/xx unknown
- 1998-03-12 ES ES98912929T patent/ES2146192T1/es active Pending
- 1998-03-12 SK SK1221-99A patent/SK122199A3/sk unknown
- 1998-03-12 PL PL98336464A patent/PL336464A1/xx unknown
- 1998-03-12 WO PCT/US1998/004916 patent/WO1998041232A2/en not_active Application Discontinuation
- 1998-03-12 BR BR9810409-8A patent/BR9810409A/pt not_active IP Right Cessation
- 1998-03-12 SI SI9820032A patent/SI20110A/sl unknown
- 1998-03-12 KR KR1019997008524A patent/KR20000076420A/ko not_active Application Discontinuation
- 1998-03-12 CN CN98805124A patent/CN1269722A/zh active Pending
- 1998-03-12 NZ NZ337769A patent/NZ337769A/xx unknown
- 1998-03-12 TR TR1999/02615T patent/TR199902615T2/xx unknown
- 1998-03-12 JP JP54063398A patent/JP2002504091A/ja active Pending
-
1999
- 1999-09-17 NO NO994506A patent/NO994506L/no unknown
- 1999-10-13 BG BG103808A patent/BG103808A/xx unknown
Also Published As
Publication number | Publication date |
---|---|
SI20110A (sl) | 2000-06-30 |
AU6760498A (en) | 1998-10-12 |
WO1998041232A3 (en) | 2000-10-05 |
BG103808A (en) | 2000-07-31 |
NZ337769A (en) | 2002-09-27 |
JP2002504091A (ja) | 2002-02-05 |
CN1269722A (zh) | 2000-10-11 |
AU734756B2 (en) | 2001-06-21 |
ES2146192T1 (es) | 2000-08-01 |
WO1998041232A2 (en) | 1998-09-24 |
TR199902615T2 (xx) | 2000-03-21 |
BR9810409A (pt) | 2000-08-22 |
CA2282845A1 (en) | 1998-09-24 |
EP0998300A1 (de) | 2000-05-10 |
IL131815A0 (en) | 2001-03-19 |
HUP0104439A2 (hu) | 2002-04-29 |
HUP0104439A3 (en) | 2002-08-28 |
SK122199A3 (en) | 2000-12-11 |
ID22975A (id) | 1999-12-23 |
DE998300T1 (de) | 2001-03-01 |
KR20000076420A (ko) | 2000-12-26 |
NO994506D0 (no) | 1999-09-17 |
NO994506L (no) | 1999-11-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL336464A1 (en) | Method of and compositions for modulating reactivity in respect to corticosteroids i | |
EP0960019A4 (de) | Verfahren zur herstellung von repliken und damit benutzte zusammensetzungen | |
PL320487A1 (en) | Haemorrhoidal compositions and method of applying them | |
US5683503B1 (en) | Composition for and method of pumping concrete | |
PL342475A1 (en) | Method of and composition for whitening teeth | |
PL327617A1 (en) | Compositions for and methods of treating osseous insufficiency | |
EP0850042A4 (de) | Zusammenzetzung und Verfahren zur Remineralisierung der Zähne | |
HK1134025A1 (en) | Compositions and kits for enhancing delivery of therapeutic agents to cells | |
ZA973160B (en) | Compositions and processes for photogeneration of acid | |
PL323623A1 (en) | Cosmetic composition in the form of elastic paste and method of making same | |
AU4243397A (en) | Methods for in vivo reduction of iron levels and compositions useful therefor | |
EP1119365A4 (de) | Zusammensetzung und methode zur verwendung von tumorzellen | |
PL325469A1 (en) | Cleaning composition and method of giving extensive viscosity to cleaning compositions | |
AU7127600A (en) | Methods and compositions for modulating responsiveness to corticosteroids | |
AU5383298A (en) | Compositions and methods for enhancement of dehydroepiandrosterone | |
GB2313781B (en) | Slurry composition for cosmetic product and method of use | |
PL324461A1 (en) | Synergic herbicidal composition and method of using same | |
PL317197A1 (en) | Compositions for and method of treating sclerosis multiplex | |
IL113438A0 (en) | Compositions and methods for cell transformation | |
EP0903080A4 (de) | Zusammensetzung und verfahren zur bekämpfung roten algenblüte | |
AU3646797A (en) | Composition and method to remove asbestos | |
AU1587499A (en) | Environmentally safe detergent composition and method of use | |
AU6014698A (en) | Filter aid protein-polysaccharide complex composition and method of use | |
AU3646897A (en) | Composition and method to remove asbestos | |
GB9607111D0 (en) | Liquid compositions containing binders and methods of using them |